Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report  Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.
The Indication pipeline Insight Reports provides client with Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 products across the globe. It comprehensively includes:
  • Comparative study of drugs under development.
  • Information on several other drugs as well among which 10 are in phase III, 25 in phase II, 49 in phase I, 2 in phase 0 13 in pre – clinical and 30 inactive and 6 are discontinued.
  • R&D activities and technologies used along with the pipeline molecules in development.
  • Information related to collaborations, in-licensing and out-licensing deals.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Head and Neck Squamous Cell Carcinoma helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.

 

DelveInsight is offering the Report at a price of US 2,250 as a single user license, USD 4,500 as a site license and USD 6,750 as a Global/Enterprise License.
For more information on Pipeline Insight Reports, email at info@delveInsight.com
About Us:
DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

  Pancreatic Cancer-Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report   Pancreatic Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.
The Indication pipeline Insight Reports provides client with details Pancreatic Cancer Pipeline products across the globe. It comprehensively includes:
  • Comparative study of drugs under development.
  • Information on several other drugs as well among which 12 are in phase III, 39 in phase II, 39 in phase I, 13 in pre – clinical and 41 in dormant phase.
  • R&D activities and technologies used along with the pipeline molecules in development.
  • Information related to collaborations, in-licensing and out-licensing deals.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
Pancreatic Cancer -Pipeline Insights, 2016 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Pancreatic Cancer helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.
DelveInsight is offering the Report at a price of USD 2,250 as a single user license, USD 4,500 as a site license and USD 6,700 as a Global/Enterprise License.
For more information on Pipeline Insight Reports, email at info@delveInsight.com

 

Contact Us:
DelveInsight Business Research
New Delhi-110075, India
Phone: +91-11-45689769, +91 9650213330
Website: http://delveinsight.com
About Us
DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

 

 

Peripheral Lung Cancer-Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report Peripheral Lung Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.

The Indication pipeline Insight Reports provides client with details on Peripheral Lung Cancer Pipeline products across the globe. It comprehensively includes:

  • Comparative study of drugs under development.
  • Information on several other drugs as well among which 1 are in phase III, 5 in phase II, 3 in phase I, 3 in pre – clinical and 6 in dormant phase.
  • R&D activities and technologies used along with the pipeline molecules in development.
  • Information related to collaborations, in-licensing and out-licensing deals.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

Peripheral Lung Cancer-Pipeline Insights, 2016 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Peripheral Lung Cancer helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.

DelveInsight is offering the Report at a price of US 1,450 as a single user license, USD 2,900 as a site license and USD 4,500 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015

Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA.

It is an autoimmune disorder when body’s own immune cell starts attacking healthy cells. This results in inflammation. It is also known as “systemic onset juvenile rheumatoid arthritis”It makes the joints inflamed and stiff for more than six weeks.

DelveInsight report on Systemic Juvenile Idiopathic Arthritis provides comparative study of drugs under development. The report provides assessment of Tofacitinib pipeline drug by Pfizer Phase III. In addition to this, the report imparts information on several other drugs as well.

Key Highlights of Report:

  • Comprehensive insights about pipeline drugs across this indication
  • Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages
  • Therapeutics assessment by monotherapy and combination products and molecule type drug information
  • Companies involved in therapeutic development of the products
  • Discontinued and dormant products

DelveInsight is offering the Report at a price of US 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

.